


Bradycardia in Ophthalmic Surgery: A Care-Bundle, Not Drug-to-Drug, Comparison [Letter]

Yu-Tung Lin¹, Wen-Ting Chang², Ming-Hui Hung¹ ²

¹School of Medicine, Tzu Chi University, Hualien, Taiwan; ²Department of Anesthesiology, National Taiwan University Hospital, Taipei, Taiwan

Correspondence: Ming-Hui Hung, Department of Anesthesiology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 100225, Taiwan, Email hung.minghui@gmail.com

Dear editor

Wu et al report a lower incidence of intraoperative bradycardia with rocuronium–sugammadex versus cisatracurium–neostigmine in ophthalmic surgery.¹ While the topic is clinically important, several features limit causal interpretation, and the drug-to-drug framing of the title may mislead readers.

First, the rocuronium arm was delivered as a self-pay anesthesia package that included bispectral index monitoring, with higher bispectral index use and lower volatile and opioid consumption. This represents a care bundle rather than a single pharmacologic exposure, yet the title and conclusions attribute the difference to drug choice alone. In addition, bradycardia occurred primarily during ocular manipulation, whereas reversal agents were administered only at the end of anesthesia. The primary endpoint therefore largely preceded any plausible effect of neostigmine versus sugammadex, making the drug-pair comparison misleading.

Second, sample size justification also raises concerns. The authors based their calculation on Cohen's $f^2=0.15$, which represents a medium effect size for multiple linear regression. However, f^2 is defined for continuous outcomes, not binary endpoints; applying it to logistic regression is inappropriate. For binary outcomes, the relevant determinant is the number of events. In reality, only 36 bradycardia events occurred, while 10 covariates were entered into the model, yielding an events-per-variable ratio of approximately 3.6, well below recommended thresholds for logistic regression stability.² Such overfitting risks unstable effect estimates. This concern is amplified by internal inconsistencies: the abstract reports an odds ratio (OR) of 0.08 with 95% confidence interval (CI) 0.02–0.94 ($p=0.001$), a combination that is internally inconsistent because a CI extending close to 1.0 would correspond to a borderline p value near 0.05, not 0.001. Table 4 of the original article instead reported OR 0.08 with 95% CI 0.02–0.29 ($p<0.001$). These discrepancies raise further doubts about the reliability of the reported association.

Third, extubation time further illustrates internal inconsistency. Although the Methods section states extubation was performed only after train-of-four ratio >0.9 , Table 2 shows identical times of 5.0 (5.0–10.0) minutes in both groups. Given sugammadex's well-established pharmacologic advantage, such equivalence is implausible. Meta-analyses consistently demonstrate that sugammadex accelerates extubation by several minutes compared with neostigmine.³ The absence of difference here implies that extubation was driven largely by workflow factors or inconsistently applied criteria, undermining the validity of this endpoint.

Additional concerns include a likely mis-specified sevoflurane row in Table 4, lack of fresh gas flow reporting despite its central role in volatile consumption,⁴ absence of data on preoperative rate-limiting medications or anesthetist/surgeon clustering, and unaddressed collinearity between bispectral index use and bundle exposures. A structured summary of these issues is provided in [Supplementary Table 1](#).

We respectfully suggest redefining the exposure at the bundle level, re-justifying sample size under a binary outcome framework with fewer or penalized covariates, correcting reporting inconsistencies, and standardizing key variables such



as fresh gas flow and extubation criteria. These clarifications would allow a more robust interpretation of whether bradycardia prevention relates to drug choice or broader anesthetic strategies.

Acknowledgments

During the preparation of this work, we used OpenAI's ChatGPT-4o (2025) to improve language and readability of the manuscript. We reviewed and edited the content as needed and take full responsibility for the content of the publication.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

The authors reported that there is no funding associated with the work featured in this communication.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Wu SC, Chin JC, Hung KC, Hsu CY, Tsai YF, Illias AM. Comparison of rocuronium and cisatracurium in ophthalmic surgeries in association with the incidence of intraoperative bradycardia—a retrospective study. *Drug Des Devel Ther.* 2025;19:7247–7257. doi:10.2147/DDDT.S532985
2. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol.* 1996;49(12):1373–1379. doi:10.1016/s0895-4356(96)00236-3
3. Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. *J Clin Anesth.* 2016;35:1–12. doi:10.1016/j.jclinane.2016.06.018
4. Feldman JM, Sherman JD. Efficient inhaled anaesthetic delivery requires managing fresh gas flow from induction through emergence. *Br J Anaesth.* 2024;133(6):1507–1510. doi:10.1016/j.bja.2024.06.024

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S568407>